Matthew Winkler - Jun 1, 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Matthew Winkler, by Brian McKelligon, as Attorney-in-Fact
Stock symbol
AKYA
Transactions as of
Jun 1, 2023
Transactions value $
$0
Form type
4
Date filed
6/5/2023, 05:54 PM
Previous filing
Jun 3, 2022
Next filing
Jun 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy) Award $0 +56.3K $0.00 56.3K Jun 1, 2023 Common Stock 56.3K $5.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.